Company / SG&A Expense
Emergent BioSolutions Inc. SG&A Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$186.1M
FY2025
5-year range
$186.1M / $368.4M
FY2021-FY2025
Trend
-39.6%
vs FY2024
Sector context
#74 of 213
Health Care
What the data says
At $186M, Emergent BioSolutions Inc.'s sg&a expense ranks #140 of 213 in the Health Care sector. SG&A Expense has fluctuated over the past 10 years, ranging from $143M in FY2017 to $368M in FY2023.
Based on SEC 10-K filings.
$186M in FY2025 with a 5-year CAGR of -9.3%.
Improved from $368M to $186M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- -18.2%
- 5-Year CAGR
- -9.3%
- 10-Year CAGR
- -
Sector benchmark
#140 of 213 in Health CareTop 65% of 213This company $186.1M Sector average $722.3M
▼
-74.2% below sector average
Key checks
Key Insights
- 5-year CAGR of -9.3%, indicating a declining trend.
- In FY2025, sg&a expense decreased 39.6% year-over-year.
- Ranks #74 out of 213 companies in the Health Care sector.
- Peak sg&a expense was recorded in FY2023.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $186.1M | -39.6% |
| FY2024 | $308.0M | -16.4% |
| FY2023 | $368.4M | +8.5% |
| FY2022 | $339.5M | -2.6% |
| FY2021 | $348.7M | +15.0% |
| FY2020 | $303.3M | +10.9% |
| FY2019 | $273.5M | +91.1% |
| FY2018 | $143.1M | +0.1% |
| FY2017 | $142.9M | -0.1% |
| FY2016 | $143.1M | +18.1% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026